Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

23andMe

FDA reins in Google-backed genetics company 23andMe

Health-related genetic test service put on hold pending US regulatory review

- PMLiVE

Survey to gauge impact of doctor-patient talks in diabetes

Lilly and Boehringer sponsor worldwide study

- PMLiVE

Avanir to co-promote Merck’s diabetes drugs in the US

Will market Januvia and Janumet to care homes

- PMLiVE

Boehringer’s first cancer drug leads EMA recommendations

Afatinib recommended for lung cancer under brand name Giotrif

- PMLiVE

AZ and BMS try again with Forxiga in the US

Pharma companies re-submit diabetes drug to the FDA for approval

Roche - Basel

Late-stage blow to Roche’s diabetes ambitions

Halts development of aleglitazar on safety and efficacy concerns

- PMLiVE

AstraZeneca and NGM form diabetes/ obesity partnership

Will use MedImmune arm to develop treatments that target gastrointestinal hormones

National Institute for Health and Care Excellence NICE logo

NICE reverses negative guidance for Forxiga in diabetes

Final draft guidance backs the use of BMS/AstraZeneca’s SGLT-2 inhibitor in certain patients

- PMLiVE

Merck & Co enters $430m diabetes deal with Abide

Will target group of enzymes known as serine hydrolases

- PMLiVE

Interview: Peter Meeus, Novo Nordisk

The managing director of Novo Nordisk UK discusses how education and new partnerships are helping fight the battle against the country’s worsening diabetes crisis

- PMLiVE

Infographic: Type 2 diabetes in Brazil

Key facts about the chronic condition's impact in the emerging market

- PMLiVE

Brazil: Patient access and education in type 2 diabetes

As the prevalence of diabetes increases in Brazil, the healthcare system needs to respond 

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links